Search Bar & Filters
Found 70 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.
Actively Recruiting
Researchers are exploring new treatments for high-risk non-muscle invasive bladder cancer HR NMIBC, a type of cancer that affects the bladder lining without spreading to the bladder muscle or beyond. This research focuses on the safety and tolerability of MK-3120, a study drug, following the standard tumor removal procedure called transurethral resection of the bladder tumor TURBT. The study is a Phase 12 clinical trial investigating MK-3120 in people with HR NMIBC who are either Bacillus Calmette-Gurin BCG-nave or BCG-exposed. Participants will receive MK-3120 through intravesical administration, meaning the drug is delivered directly into the bladder. The treatment schedule begins with once-weekly doses for the first 6 weeks, followed by once-monthly doses for 9 months. This dosing plan aims to evaluate the drugs safety and effects over a period that includes the initial intensive phase and a maintenance phase. During the study, participants will be monitored closely for dose-limiting toxicities and adverse events up to about 24 months. Researchers will assess if participants discontinue treatment due to side effects within roughly 12 months. The main goal is to evaluate the safety profile of MK-3120 and observe its complete response rate up to approximately 3 months. Participants can expect regular assessments, including safety monitoring and treatment visits, throughout their involvement in the trial lasting several months to years.
Actively Recruiting
Researchers are studying the safety and tolerability of Sacituzumab Tirumotecan when given directly into the bladder in people with intermediate-risk non-muscle invasive bladder cancer NMIBC. This phase 12 open-label study aims to find the highest dose participants can take without significant problems and to select a dose for future studies to evaluate how well the drug works. Participants will receive intravesical Sacituzumab Tirumotecan once a week for six weeks. The study may also include the use of rescue medications and supportive care measures to manage side effects. The study is designed as a single group where all participants receive the experimental treatment. During the study, participants will be closely monitored for dose-limiting toxicities and adverse events, with safety assessments over approximately 6 to 10 weeks. Researchers will also measure drug levels in the blood and evaluate treatment response up to 24 months. The total participation duration can be up to two years for some outcome measures.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the FloStent, a medical device used for treating men experiencing symptoms of Benign Prostatic Hyperplasia BPH. The study compares the FloStent implant procedure to a sham procedure without deploying the device. It involves men aged 45 and older with symptomatic BPH to better understand how this device may impact urinary symptoms. Participants will undergo a flexible cystoscopy procedure. Those randomized to the treatment group will receive the FloStent implant during this procedure, while those in the control group will have the cystoscopy without the implant deployment, serving as a sham treatment. The study is randomized, double-blind, and includes parallel groups to compare outcomes over time. Throughout the study, participants will be assessed on changes in their International Prostate Symptom Score IPSS over 12 months. Researchers will monitor symptom improvements at 3, 6, and 12 months to evaluate response rates. Participants will complete study visits and follow the protocol to help researchers gather data on the devices safety and impact on urinary symptoms.
Actively Recruiting
Researchers are evaluating the safety, tolerability, immune response, and pharmacokinetics of UGN-501, a chimeric oncolytic adenovirus, given directly into the bladder for adults with recurrent non-muscle invasive bladder cancer NMIBC. This Phase 1, open-label, dose-escalation study focuses on participants with high-grade and low-grade Ta andor T1 disease or carcinoma in situ CIS, aiming to find the recommended dose for further study. Participants will undergo a 12-week Induction Period with six weekly intravesical instillations of UGN-501. Those with certain disease types who respond or do not have recurrence will continue into a Maintenance Period, receiving three weekly instillations every three months from Month 3 to Month 12. Disease assessments occur every three months up to 15 months or until recurrence, progression, or death. The study may add other intervention arms or dose expansions in future amendments. During the study, participants will have regular evaluations including monitoring for dose-limiting toxicities, adverse events, drug levels in blood and urine, and immune response. Disease status will be assessed at specified intervals, with follow-up lasting up to 15 months. The main outcomes measured include safety, complete response rate at 3 months, and recurrence-free survival at 6 months, along with detailed pharmacokinetic and viral shedding analyses.
Actively Recruiting
Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.
Actively Recruiting
Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.
Actively Recruiting
Researchers are studying the safety and effectiveness of intravitreal KSI-101 injections in adults with macular edema caused by inflammation, called Macular Edema Secondary to Inflammation MESI. This Phase 3 clinical trial aims to evaluate how well KSI-101 works compared to a sham injection in improving vision for people with this condition. Participants will receive one of three treatments KSI-101 at 5 mg or 10 mg doses injected into the eye every 4 weeks for six months, followed by dosing tailored to individual needs, or a sham injection following the same schedule. The study is randomized, double-masked, and controlled to ensure unbiased results. During the trial, participants will undergo vision tests to measure changes in best-corrected visual acuity BCVA over 24 weeks. Researchers will monitor safety and treatment effects throughout the study. The trial is expected to run until November 2027, with participants receiving regular assessments and follow-ups to track their eye health and response to treatment.
1-10 of 70
1